Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial

Table 3 Treatment Intensification Rates, Baseline Risk Factor Levels, Declines and Adjusted Mean Differences During Follow-up - Processed vs. Not Processed Patients, Intervention Centers Only, by Priority Level

		Processed			Not Processed
Priority	Percent Processed ^†	Intensified within 3 mos (%)	Baseline Mean Risk Factor Level ^‡	Unadjusted Decline ^¶	Intensified within 3 mos (%)	Baseline Mean Risk Factor Level ^‡	Unadjusted Decline ^¶	Adjusted Difference (Processed – not Processed) During Follow-up (95% CI) ^€
1: SBP ≥ 140 mmHg	45	40.5	153.4	13.1	28.8	153.0	14.1	1.01
1: SBP ≥ 140 mmHg	45	40.5	153.4	13.1	28.8	153.0	14.1	(0.30, 1.75)
2: LDL-c ≥ 130 mg/dL	46	36.3	152.8	25.9	21.0	153.4	24.0	-0.6
2: LDL-c ≥ 130 mg/dL	46	36.3	152.8	25.9	21.0	153.4	24.0	(-3.4, 2.2)
3: A1c ≥ 9%	47	32.6	10.3	1.0	26.7	10.2	1.0	-0.03
3: A1c ≥ 9%	47	32.6	10.3	1.0	26.7	10.2	1.0	(-0.19, 0.14)
4:SBP 130-139^£	29	27.4	138.9	5.6	21.1	138.4	6.2	1.06
4:SBP 130-139^£	29	27.4	138.9	5.6	21.1	138.4	6.2	(0.44, 1.69)
5: LDL-c 100-129 mg/dL	30	29.2	111.2	10.4	16.8	111.4	10.0	0.63
5: LDL-c 100-129 mg/dL	30	29.2	111.2	10.4	16.8	111.4	10.0	(-0.95, 2.22)
6. A1c 7-8.9%	28	28.9	7.6	-0.1	25.3	7.5	-0.1	-0.03
								(-0.09, 0.04)

^† Processed: Record review and outreach initiated by staff in response to identification of eligibility for treatment intensification.
^‡ Based on the last value recorded before follow-up begins; i.e., the value that qualified patient for treatment intensification.
^¶ Based on the first value recorded after 3 months follow-up; if no values recorded between 3 and 12 months follow-up, the latest value recorded during first 3 months follow-up was used.
^€ From repeated measures models using all available values during follow-up,with adjustment for age, gender, race-ethnicity, baseline risk factor value, number of medications for the risk factor at baseline, and days of follow-up at time of each measurement. Negative value indicates that the adjusted values were lower in the processed group during follow-up.
^£ Only patients with diabetes mellitus and/or chronic kidney disease were eligible for the target of SBP <130 mmHg.

ISSN: 1472-6963